- Home
- NEO vs XNCR Comparison
NEO vs XNCR Comparison
Compare NEO & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEO | XNCR |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1999 | 2013 |
Fundamental Metrics
Financial Performance| Metric | NEO | XNCR |
|---|---|---|
| Price | $12.46 | $15.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $11.38 | ★ $22.78 |
| AVG Volume (30 Days) | ★ 1.7M | 838.7K |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $709,162,000.00 | $150,132,000.00 |
| Revenue This Year | $10.90 | $18.81 |
| Revenue Next Year | $9.88 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 10.10 | ★ 38.16 |
| 52 Week Low | $4.72 | $6.92 |
| 52 Week High | $19.12 | $24.94 |
Technical Indicators
Market Signals| Indicator | NEO | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 67.58 | 44.81 |
| Support Level | $11.46 | $15.30 |
| Resistance Level | $12.19 | $16.17 |
| Average True Range (ATR) | 0.40 | 0.91 |
| MACD | -0.03 | -0.30 |
| Stochastic Oscillator | 85.90 | 2.36 |
Price Performance
Historical ComparisonAbout NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.